immunotherapy

Ukusebenzisa I-Immunotherapy Ukwelapha Umdlavuza Wesigaba Sakamuva

  Isingeniso I-Immunotherapy isiphenduke indlela eyisisekelo ekwelashweni komdlavuza, ikakhulukazi ekwelashweni komdlavuza okusezingeni eliphezulu okukhombise ukusebenza kahle okuncane ngemithi ejwayelekile. Lolu hlelo lokusebenza olusha..

Ukwelashwa kwe-Tumor-Infiltrating Lymphocyte (TIL) e-China

Feb 2024: Tumor-infiltrating lymphocyte (TIL) therapy treatment is a potential method that utilizes the body's immune system to fight solid tumors. This therapeutic area in China is advancing rapidly because of the nation's incr..

Ukwelapha Umdlavuza Kwamahhala E-China Ngaphandle Kokwephula Ibhange: Umhlahlandlela Walabo Abawudinga Kakhulu

Ukwelashwa kwamahhala komdlavuza e-China kunikeza ithemba nokwelashwa kubantu abadinga usizo. Ngakho-ke, uma ungakwazi ukukhetha ukwelashwa komdlavuza ngenxa yezindleko zakho ezinkulu, lo mhlahlandlela uhloselwe wena ngokukhethekile. Thola ukuthi inhlangano ehlonishwa kanjani..

Iqhaza Le-Immunotherapy Ekwelashweni Kwe-Lymphoma

Uma ufunda lokhu, wena noma mhlawumbe omunye wabathandekayo bakho usohambweni okungekho muntu ohlela ukuluthatha—indlela yokubhekana nomdlavuza. Siyaqonda ukuthi lo mgwaqo ugcwele ukungaqiniseki, ukwesaba, kanye nezikhathi lapho uzwakala khona.

I-TIL immunotherapy, Ukwelashwa kwe-TILs, I-Tumor Infiltrating Lymphocytes

I-Tumor Infiltrating lymphocytes (TIL) Immunotherapy eNdiya

Ephreli 2023: Ukusebenzisa amasosha omzimba ukulwa namaseli omdlavuza kuwumgomo wendlela ethembisayo yokwelapha umdlavuza eyaziwa nge-tumor infiltrating lymphocytes (TIL) immunotherapy. Le nqubo ihlanganisa ukuthatha amaseli omzimba abizwa ngokuthi i-TI.

I-American Society of Hematology, I-Carteyva, China, I-JW Therapeutics, i-relmacabtagene autoleucel

I-JW Therapeutics Yethula Idatha Yakamuva Yomtholampilo ku-Carteyva® ku-Follicular Lymphoma kanye ne-Mantle Cell Lymphoma eMhlanganweni Wonyaka wama-64 we-ASH

E-SHANGHAI, ECHINA, Disemba 12, 2022 Inkampani ezimele futhi enobuhlakani be-biotechnology ebizwa ngokuthi i-JW Therapeutics (HKEX: 2126) igxile ekuthuthukiseni, ekukhiqizeni, nasekudayiseni imikhiqizo ye-cell immunotherapy. Ku-64th American Society..

Ukwelashwa kwamaseli, China, I-JW Therapeutics, Shanghai

I-JW Therapeutics Imemezela Ukuthi Izidakamizwa Zayo Ze-Cell Immunotherapy Zihlomulise Ngempumelelo Iziguli Ezingama-300

I-SHANGHAI, ECHINA, Novemba 9, 2022 - I-JW Therapeutics (HKEX: 2126), inkampani ezimele nentsha ye-biotechnology egxile ekuthuthukiseni, ekukhiqizeni, nasekuthengiseni imikhiqizo ye-cell immunotherapy, imemezele ukuthi kusukela ngo-N.

2 amashumi ayisikhombisa bio, China, immunotherapy, I-JW Therapeutics, lobambiswano

I-JW Therapeutics kanye ne-2seventy bio Memezela Ubambiswano Lwesu Lokusheshisa Ucwaningo Nokuthuthukiswa Kwe-T-cell-based Immunotherapies

I-SHANGHAI, CHINA kanye ne-CAMBRIDGE, MASSACHUSETTS, US, Okthoba 27, 2022 - I-JW Therapeutics (HKEX: 2126), inkampani ezimele nentsha ye-biotechnology egxile ekuthuthukiseni, ekukhiqizeni nasekuthengiseni i-cell immunotherap.

KEYTRUDA, Merck, I-Pembrolizumab, I-Roche Tissue Diagnostics, Izinhlelo zeVentana Medical

I-Pembrolizumab ivunyelwe i-endometrial carcinoma ethuthukisiwe

Ngo-Ephreli 2022: I-Pembrolizumab (Keytruda, Merck) yagunyazwa yi-Food and Drug Administration njenge-ejenti eyodwa yeziguli ezine-endometrial carcinoma ethuthukisiwe okuyi-microsatellite instability-high (MSI-H) noma ukulungisa okungahambi kahle.

I-PD-1 inhibitor immunotherapy ye-B cell lymphoma

Ukubuyekeza okubhalwe yiYoung, MD, Anderson Cancer Center, e-USA kuchaze ukusetshenziswa kwe-PD-1 inhibitor immunotherapy ku-B-cell lymphoma. (Igazi. Uhlobo oluku-inthanethi ngoNovemba 8, 2017. doi: 10.1182 / blood-2017-07-740993.) PD-1 immune ..